Potential new therapy for Crohn’s, colitis identified
Alternative to anti-inflammatory therapies reduces IBD symptoms in mice
Researchers have found a compound that may treat inflammatory bowel disease without directly targeting inflammation. The compound tamps down the activity of a gene linked to blood clotting. They discovered that the gene was turned on at sites of intestinal inflammation and damage, and blocking its activity reduces IBD symptoms in mice.
The findings, published March 6 in Science Translational Medicine, may be a path to new therapeutic options for people whose IBD can’t be controlled effectively with current treatments.
“There’s a lot of interest in novel therapeutic approaches for IBD because inhibiting inflammatory molecules doesn’t work for all patients,” said senior author Thaddeus S. Stappenbeck, MD, PhD, the Conan Professor of Laboratory and Genomic Medicine. “We found a unique target that’s not an inflammatory molecule, and yet blocking it reduces inflammation and signs of disease, at least in mice. If further research bears out our findings, we think this target could be helpful to a greater number of patients.”
“What’s most exciting here is that SERPINE-1 and its protein seems to be most highly expressed in people with the most severe disease and those who don’t respond to immunosuppressive biologics,” Stappenbeck said. “No one’s ever thought of targeting something like this. But here we’ve found something that might help lots of people with IBD, especially the ones who aren’t benefiting much from current therapies.”
Read full article at https://www.sciencedaily.com/releases/2019/03/190306143022.htm